Trial · NCT07893327
Evaluation of the Effect of Regular Physical Exercise in Breast Cancer.
NCT07893327, Not applicable, Recruiting, Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of the Effect of Regular Physical Exercise in Breast Cancer. Trials, record NCT07893327. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893327
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of the Effect of Regular Physical Exercise in Breast Cancer.
- NCT number
- NCT07893327
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Interventions
- Supervised exercise program
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Health-Related Quality of Life | through study completion, an average of 1 year | Evaluate the effect of a regular physical exercise intervention compared with standard care on health-related quality of life in patients with breast cancer using EORTC QLQ-BR42 questionnaires. |
| Secondary | Change in physical activity level asseseed by IPAQ. | through study completion, an average of 1 year | Physical activity level will be assessed using the International Physical Activity Questionnaire (IPAQ). Higher scores indicate higher levels of physical activity. |
| Secondary | Bioelectrical impedance analysis (BIA). | through study completion, an average of 1 year | Assess changes in nutritional status and body composition using bioelectrical impedance analysis (BIA). |
| Secondary | Change in Mediterranean Diet Adherence Screener (MEDAS) score | through study completion, an average of 1 year | Adherence to the Mediterranean dietary pattern will be evaluated using the MEDAS questionnaire. |
| Secondary | Change in dietary intake | through study completion, an average of 1 year | Assess dietary intake using a Food Frequency Questionnaire and a three-day dietary record. |
| Secondary | Change in sleep quality assessed by Pittsburgh Sleep Quality Index (PSQI). | through study completion, an average of 1 year | Sleep quality will be assessed using the Pittsburgh Sleep Quality Index. |
| Secondary | Change in depressive symptoms assessed by Patient Health Questionnaire-9 (PHQ-9). | through study completion, an average of 1 year | Depressive symptom severity will be measured using the Patient Health Questionnaire-9. |
| Secondary | Change in anxiety symptoms assessed by IPIP-ANX. | through study completion, an average of 1 year | Anxiety symptoms will be assessed using the IPIP Anxiety scale. |
| Secondary | Change in perceived cognitive function assessed by FACT-Cog. | through study completion, an average of 1 year | Cognitive function will be assessed using the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) |
| Secondary | Genetic and epigenetic biomarkers measured by Illumina Infinium Methylation chips. | Baseline | Genetic and epigenetic biomarkers will be assessed at baseline through analysis of selected SNPs and DNA methylation profiles using commercially available panels related to cancer progression, lifestyle factors, metabolic regulation, hematopoietic alterations, and microbiota-associated pathways. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893327
GET https://conductscience.org/api/trials/v1/NCT07893327/registered